CyndRx Projects
CyndRx focuses on medical technology projects achievable within a 1-4 year timeline. Our goal is to develop innovative and disruptive technologies leveraging our in-house industry experiences and expertise to provide high-value return of investment.
Currently, CyndRx is fully dedicated to the development and commercialization of a market-differentiating vascular closure device platform, AbsorbaSeal™.
- AbsorbaSeal™™ , a Vascular Closure Device (VCD) platform, with its easy-to-use delivery (3- primary step deployment), is intended to achieve hemostasis with a fully bioabsorbable sealing mechanism that allows the target vessel to heal without permanent implants, while also focusing on economic value. The AbsorbaSeal™ VCD platform is scalable from small through large bore access (5F to 22F), designed to offer an innovative, clinically and economically valuable VCD platform.
For more information, please contact us.
CAUTION: Investigational Device. Limited by Federal (or United States) Law to Investigational Use.